title: A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
abstract: The purpose of this trial was to examine the efficacy of the addition of levamisole (LEV) or interferon alfa (IFN) to an adjuvant chemotherapy with 5-fluorouracil (5-FU) in patients with stage III colon cancer. According to a 2 x 2 factorial study design, 598 patients were randomly assigned to one of four adjuvant treatment arms. Patients in arm one received 5-FU weekly for 1 year, patients in arm two 5-FU plus LEV, in arm three 5-FU plus IFN and patients in arm four 5-FU, LEV and IFN. The relative risk of relapse and the relative risk of death were significantly higher for patients treated with LEV compared with those without LEV treatment (HR 1.452, 95% CI 1.135-1.856, P=0.0028; HR 1.506, 95% CI 1.150-1.973, P=0.0027, respectively). No significant impact on survival was observed for therapy with IFN in the univariate analysis. The addition of LEV to adjuvant 5-FU significantly worsened the prognosis of patients with stage III colon cancer. Interferon alfa had no significant influence on survival when combined with adjuvant 5-FU, but increased the toxicity of therapy substantially.
authors.affiliation: Medical Department, Division of Oncology, Graz Medical School, A-8036 Graz, Austria. walter.schippinger@klinikum-graz.at
authors.forename: W
authors.initials: W
authors.lastname: Schippinger
authors.forename: M
authors.initials: M
authors.lastname: Jagoditsch
authors.forename: C
authors.initials: C
authors.lastname: Sorré
authors.forename: M
authors.initials: M
authors.lastname: Gnant
authors.forename: G
authors.initials: G
authors.lastname: Steger
authors.forename: H
authors.initials: H
authors.lastname: Hausmaninger
authors.forename: B
authors.initials: B
authors.lastname: Mlineritsch
authors.forename: R
authors.initials: R
authors.lastname: Schaberl-Moser
authors.forename: H J
authors.initials: HJ
authors.lastname: Mischinger
authors.forename: F
authors.initials: F
authors.lastname: Hofbauer
authors.forename: P
authors.initials: P
authors.lastname: Holzberger
authors.forename: M
authors.initials: M
authors.lastname: Mittlböck
authors.forename: R
authors.initials: R
authors.lastname: Jakesz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D002955:Leucovorin / Q000008:administration & dosage; D007978:Levamisole / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D016898:Interferon-alpha; D007978:Levamisole; D002955:Leucovorin; D005472:Fluorouracil